Hormone Therapy and Hair Loss: What’s Really Happening and How to Help

When Hormones Drive Hair Loss

Hair loss is among the most emotionally impactful symptoms of hormonal decline — affecting self-image, confidence, and quality of life in ways that extend well beyond the cosmetic. Understanding the hormonal drivers of hair loss is the first step toward meaningful intervention, because the most effective treatments target the underlying hormonal cause rather than the follicle itself.

Androgenetic Alopecia (Male and Female Pattern Baldness)

The most common form of hair loss in both men and women is androgenetic alopecia — follicular miniaturization driven by DHT (dihydrotestosterone), a potent androgen converted from testosterone by the enzyme 5-alpha reductase in hair follicles. DHT binds to androgen receptors in genetically susceptible follicles (particularly those on the crown and hairline in men, and diffusely in women with a specific genetic pattern), triggering progressive miniaturization — the follicle produces thinner, shorter, lighter hair with each cycle until it eventually becomes dormant.

The relationship between TRT and androgenetic alopecia is nuanced: TRT can potentially accelerate hair loss in men with genetic susceptibility to DHT-driven follicle miniaturization, because higher testosterone provides more substrate for DHT conversion. However, TRT does not cause hair loss in men without the relevant genetic predisposition. Men with significant androgenetic alopecia who are starting TRT may discuss 5-alpha reductase inhibitors (finasteride or dutasteride) with their provider — these reduce DHT production and can preserve hair while allowing testosterone optimization.

Thyroid-Related Hair Loss

Both hypothyroidism and hyperthyroidism cause diffuse hair loss (telogen effluvium) — the generalized shedding throughout the scalp rather than the patterned recession of androgenetic alopecia. Thyroid hormones regulate the hair growth cycle, and disruption in either direction shifts more follicles into the telogen (shedding) phase simultaneously. Thyroid-related hair loss is typically reversible with thyroid optimization — hair density recovers over 3–6 months once thyroid hormone levels are stable and within the optimal range.

Estrogen, Progesterone, and Hair in Women

Estrogen supports hair follicle growth phase duration (anagen), keeping more follicles actively growing simultaneously. When estrogen declines at menopause (or fluctuates erratically in perimenopause), the anagen phase shortens, more follicles shift to telogen, and net hair density decreases. This is a primary driver of the hair thinning and increased shedding that many women in their 40s and 50s report. HRT — particularly estradiol — has shown benefits for hair density in postmenopausal women in several small studies, consistent with the biological mechanism.

Progesterone may also contribute through 5-alpha reductase inhibition — progesterone is a natural, mild 5-alpha reductase inhibitor, meaning it partially reduces DHT production. Progesterone deficiency in perimenopause may contribute to increased DHT-driven hair loss in women with androgenetic susceptibility.

A Comprehensive Hair Loss Approach

At Multigen Wellness, hair loss evaluation includes assessment of thyroid function, sex hormone levels (testosterone, free testosterone, DHT when indicated, estradiol, progesterone), ferritin (iron deficiency is a major and frequently missed cause of diffuse hair loss), and autoimmune markers when appropriate. Treatment of documented hormonal contributors is the most physiologically rational first approach — topical minoxidil, dermatology consultation, and finasteride are considered alongside hormonal management based on the individual picture.

If hair loss is affecting your confidence and quality of life, a comprehensive hormonal evaluation is your first step. Call Multigen Wellness at (800) 259-0015.